Sitryx
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bellhouse Building Magdalen Centre 101, ...Phone Number
+44 2037095700Website
www.sitryx.comRevenue
$8.5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
1
1
1
1
About Sitryx
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field of immunology and metabolism; Houman Ashrafian, Luke O'Neill, Jonathan Powell, Jeff Rathmell, Michael Rosenblum and Paul Peter Tak. Together they have published thousands of papers in the field, making multiple key breakthroughs in the company's understanding of how critical energetic status is to the behavior of immune cells and in the broader field of immunology. In 2018, Sitryx raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. In 2020, Sitryx formed an exclusive global licensing and research collaboration with Eli Lilly andRead more
Sitryx Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sitryx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Sitryx, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Sitryx has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Sitryx launches new products
Click to see if Sitryx had a recent Job posting/layoffs
Check out if Sitryx is spiking on competitors!
Funding: Get notified immidiatlly once Sitryx has new funding data
Earning: See what the market has to say on Sitryx recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Sitryx
Recommended Actions
Reach out to Masked Content who joined Sitryx as Masked Content
Find more new buyers
Compare Similar Companies to Sitryx
Compare insights from companies similar to Sitryx, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sitryx is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sitryx is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sitryx.
Sitryx financials insights
Gather financial insights about Sitryx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$30M
2023
Other Financing Round
$39M
Sitryx Tech Stack
A closer look at the technologies used by Sitryx
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Person-Based
Person-Based
Person-Based
Sitryx News & Media
Sitryx to Participate in Upcoming Investor Conferences
Oxford, UK and Boston, MA – May 18, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences:First-in-Class Oral PKM2 Modulator SYX-5219 Phase 1a Trial Data to be Presented at SID 2026
Oxford, UK and Boston, MA – 13 May 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, will share positive findings from a Phase 1a trial of its lead clinical program, SYX-5219, at the 83rd Society for Investigative Dermatology (SID) Annual Meeting, taking place in Chicago from today until 16 May.Sitryx nominates novel, oral GLS1 inhibitor for clinical development in moderate to severe asthma
Oxford, UK and Boston, MA – 2 April 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the nomination of its lead glutaminase-1 (GLS1) inhibitor as the latest development candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a Clinical Trial Authorization (CTA).Sitryx to participate in upcoming April investor conferences
Oxford, UK and Boston, MA – March 26, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in the following upcoming investor conferences:
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sitryx
Sign Up For FreeTo access detailed company insights
Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-inflammation and immuno-oncology. Sitryx's proprietary science is led by a highly experienced management team and supported by world class academic founders. Sitryx was founded by six world-leading researchers in the field... Read More
